The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis
Autor: | Li Xiang Li, Yan Zhang, Yan Qing Li, Xiu Li Zuo, Chao Liu, Bing Cheng Feng |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Endoscopic Mucosal Resection Vonoprazan Cochrane Library Shrinkage rate Gastroenterology 03 medical and health sciences 0302 clinical medicine Postoperative Complications Internal medicine Medicine Humans Pyrroles Stomach Ulcer Formation rate Sulfonamides business.industry Proton Pump Inhibitors Odds ratio Endoscopic submucosal dissection Confidence interval Treatment Outcome 030220 oncology & carcinogenesis Meta-analysis 030211 gastroenterology & hepatology business |
Zdroj: | Journal of digestive diseasesREFERENCES. 20(10) |
ISSN: | 1751-2980 |
Popis: | Objective Artificial ulcers after endoscopic submucosal dissection (ESD) are usually treated by proton pump inhibitors (PPIs) in clinical setting. Vonoprazan, a newly developed potassium-competitive acid blocker, has recently been used to treat post-ESD ulcers. We aimed to evaluate the efficacy and safety of vonoprazan on the healing of post-ESD artificial ulcers compared with those of proton pump inhibitors (PPIs) using a meta-analysis. Methods EMBASE, MEDLINE, Scopus and Cochrane Library databases were searched for all studies comparing the efficacy and safety of vonoprazan with those of PPIs in the treatment of post-ESD ulcers. Results Fourteen articles with 1328 patients were included in this meta-analysis. When comparing ulcer shrinkage rate, vonoprazan showed a better efficacy than PPIs (mean difference 0.56, 95% confidence interval [CI] 0.18-0.93). Vonoprazan also led to a higher scar formation rate (odds ratio [OR] 1.58, 95% CI 1.00-2.47) and showed a potential superiority on reducing the risk of post-ESD bleeding compared with PPIs, with a pooled OR of 0.69, although there was no statistically significant difference. Conclusions Compared with PPIs, vonoprazan showed a better efficacy in ulcer shrinkage rate and achieved more complete healing in the treatment of post-ESD ulcers. Vonoprazan did not induce any incremental risk of post-ESD bleeding as well. It may be an appropriate choice in the management of artificial ulcers after ESD. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |